ABEONA THERAPEUTICS INC. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company. On April 28, 2025, the FDA approved ZEVASKYN (prademagene zamikeracel), the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company is currently in the early stages of commercialization, with Qualified Treatment Centers (QTCs) established in California, Illinois, and Colorado. The company also maintains a preclinical pipeline of AAV-based gene therapies for ophthalmic diseases.
Key Financial Metrics
| Metric ($ in thousands) | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenues | $0 | $0 | $400 | $0 |
| Net Income (Loss) | $(5,161) | $(30,269) | $91,643 | $(54,441) |
| Operating Loss | $(24,018) | $(15,345) | $(66,537) | $(47,539) |
| Cash & Equivalents | $82,884 | $23,357 | $82,884 | $23,357 |
| Short-term Investments | $124,233 | $74,363 | $124,233 | $74,363 |
| Total Debt (Current + Long-term) | $19,751 | $18,963 | $19,751 | $18,963 |
| Warrant Liabilities | $22,566 | $32,014 | $22,566 | $32,014 |
Note: YTD 2025 Net Income includes a one-time gain of $152.4 million from the sale of a Priority Review Voucher (PRV).
Material Changes vs. Prior Period
- Revenue: The company recorded $0.4 million in license revenue YTD 2025 from a third-party option exercise for AAV capsids, compared to $0 in the prior year. No product revenue from ZEVASKYN has been recognized yet.
- Profitability: The company reported a net income of $91.6 million YTD 2025, a reversal from a $54.4 million loss in YTD 2024. This is primarily driven by the $152.4 million gain on the PRV sale. Excluding this gain, the company remains unprofitable with an operating loss of $66.5 million.
- Expenses: Selling, General, and Administrative (SG&A) expenses increased significantly to $46.2 million YTD 2025 (up 109% YoY) due to commercial launch costs, new hires, and legal fees. Research and Development (R&D) expenses decreased to $20.1 million (down 21% YoY) as certain production costs were capitalized into inventory following FDA approval.
- Liquidity: Total cash resources (cash, equivalents, and short-term investments) increased to $207.5 million as of September 30, 2025, up from $97.7 million at year-end 2024, bolstered by the PRV sale proceeds and ATM equity sales.
Guidance, Outlook, and Risks
- Commercialization Status: ZEVASKYN is approved but has not yet generated product revenue. A full batch manufactured in August 2025 could not be released due to a false positive result in a rapid sterility assay. Biopsy collection was paused and resumed in November 2025 after assay optimization.
- Regulatory Milestones: A permanent HCPCS J-code (J3389) for ZEVASKYN was established by CMS, effective January 1, 2026. The ABO-503 program for X-linked retinoschisis was selected for the FDA's Rare Disease Endpoint Advancement Pilot (RDEA) program.
- Debt & Financing: The company amended its Loan Agreement in July 2025, reducing the interest rate from 13.5% to 11.75%. It maintains an At-The-Market (ATM) agreement with $51.5 million remaining capacity.
- Risks: Key risks include the ability to successfully commercialize ZEVASKYN, potential limitations on Net Operating Loss (NOL) carryforwards due to ownership changes (Section 382 analysis pending), and supply chain disruptions due to trade policy/tariffs. The company expects to continue incurring losses until ZEVASKYN generates sufficient revenue.
Investor Verification Checklist
- PRV Gain Impact: Verify the sustainability of earnings by excluding the $152.4 million one-time PRV gain to assess core operational burn rate.
- Manufacturing Resolution: Confirm the status of the August 2025 ZEVASKYN batch and the timeline for the first commercial release following the sterility assay fix.
- Section 382 Analysis: Monitor the completion of the Section 382 ownership change analysis (expected by Dec 31, 2025) to understand limitations on using $416.1 million in NOL carryforwards.
- Debt Covenants: Review compliance with the $5 million unrestricted cash covenant under the Loan Agreement.
- Commercial Uptake: Track patient enrollment and treatment initiation at the three active Qualified Treatment Centers (QTCs).